3.82
Panoramica
Notizia
Cronologia dei prezzi
Perché EVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Evotec Se Adr Borsa (EVO) Ultime notizie
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com
8 New 4-Star Stocks - Morningstar
Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister
Evotec SE (EVO) Stock Forecasts - Yahoo Finance
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria
Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Stock Information - Evotec
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com Australia
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks
Evotec: Management Streamlines Strategy to Refocus on Core Strengths Amid Biologics Momentum - Morningstar
Antibody Discovery Market Size to Achieve USD 22,570 Mn by 2034 | Statifacts - GlobeNewswire Inc.
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - BNN Bloomberg
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Halozyme Therapeutics stock sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Annual General Meeting - Evotec
Investor Relations - Evotec
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Healthcare Sector - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com India
Evotec: Still A Speculative Buy After A Significant Decline (NASDAQ:EVO) - Seeking Alpha
Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders - Center for Biosimilars
Evotec SE ADR earnings, Revenue miss in Q3 By Investing.com - Investing.com India
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Together for Medicines That MatterEvotec - Evotec
Evotec and Biogen Idec in research agreement - Proactive financial news
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):